NCT05566028CompletedPhase 3
The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes
A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of D150, D745 and D759 Combination Therapy in Pateints with Type 2 Diabetes Inadequately Controlled with D150 Plus D759
Source: ClinicalTrials.gov · Last updated 10 Dec 2024
Brief summary (registry, in English)
The purpose of this study is to prove that the group treated with D745 in combination added that the reduction of HbA1c superior to placebo treated group added in combination.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 172 (actual)
- First submitted
- 30 Sept 2022
- Start date
- 12 Oct 2022
- Primary completion date
- 10 Jan 2024
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Diseases
- Type 2 diabetes
- NCT number
- NCT05566028
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 172
- From 12 Oct 2022 to the primary completion date, 10 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Continuous or non continuous treatment insulin within 12 weeks prior to screening
- Chronic oral or non oral corticosteroids treatment within 4 weeks prior to screening
Other illness
- Type 1 diabetes mellitus or secondary diabetes mellitus
- Patients with complications of severe diabetes such as proliferative diabetic retinopathy
Lab values
- Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- Patients with abnormal laboratory test results according to the protocol
Who the study is looking for
- between 19 years and 85 years old(male or female)
- Type 2 diabetes mellitus
- BMI between 18.5kg/m2 and 40kg/m2
- Agreement with written informed consent
Age in the registry: 19 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.